Different starting doses of oral propranolol for ulcerated infantile hemangioma
Official title: Efficacy and Safety of Different Initial Doses of Oral Propranolol in the Treatment of Ulcerated Infantile Hemangioma： a Prospective Study
Run by West China Hospital · NCT06798363 · Data updated 2026-11-12
This trial sees if different starting doses of oral propranolol help heal ulcerated infantile hemangiomas and are safe for infants.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | Any age to 1 Year |
| Sex | All |
| Enrollment | 32 (estimated) |
| Sponsor | West China Hospital Academic / other |
| Locations | 3 sites (Chengdu, Sichuan and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | September 30, 2026 |
| Study ends | March 30, 2027 |
| Registry record updated | September 21, 2026 |
| Trial ID | NCT06798363 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Infants and young children with ulcerated infantile hemangioma who can take oral propranolol and have no propranolol contraindications are ideal candidates.
✕Probably not a fit
Children who have already received other treatments for the ulcer, who cannot tolerate or are contraindicated for propranolol, or who cannot complete follow-up may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This phase 2/3 interventional study prospectively compares different initial oral propranolol doses in children with ulcerated infantile hemangiomas. Participants receive propranolol and are followed for ulcer healing, treatment-related complications, and adverse events. Children who previously received other interventions or who have contraindications to propranolol are excluded. The aim is to clarify which starting dose offers effective ulcer healing with the fewest side effects.
Why it matters
Potential benefit: If successful, the study could identify a starting propranolol dose that speeds ulcer healing while minimizing side effects for affected infants.
How similar studies have gone: Propranolol is an established treatment for infantile hemangioma and retrospective reports suggest low starting doses can be effective and safe, but prospective dose-comparison data are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. all patients with ulcer IH; 2. children with ulcer IH treated with propranolol. Exclusion Criteria: 1\) children with ulcer IH who received other therapeutic interventions were excluded; 2) Children whose families refused to participate in the study; 3) patients with contraindications to oral propranolol, such as allergy to propranolol, severe bradycardia and bronchial asthma; 4) children lost to follow-up during oral propranolol treatment; 5) children unable to oral propranolol or continue to oral propranolol due to other reasons. \-
Where it's running
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China Recruiting -
Sichuan Women and Children's Hospital
Chengdu, Sichuan, China Recruiting -
West China Second University Hospital of Sichuan University
Chengdu, Sichuan, China Recruiting
Study contacts
- Study coordinator: Yi Ji
- Email: jijiyuanyuan@163.com
- Phone: +862885423453
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.